Last reviewed · How we verify

NCT05330767

DermaClose DUKE Fasciotomy and Wound Study

Terminated Last updated 21 March 2025
What this trial tests

trial testing DermaClose Continuous External Tissue Expander Device in Wound of Skin in 7 participants. Terminated before completion.

Timeline
22 August 2022
Primary endpoint
13 November 2023
13 November 2023

Quick facts

Lead sponsorBaxter Healthcare Corporation
StatusTerminated
Study typeOBSERVATIONAL
Enrollment7
Start date22 August 2022
Primary completion13 November 2023
Estimated completion13 November 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Baxter Healthcare Corporation — full company profile →

Who can join

18 and older, any sex, with Wound of Skin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the clinical performance of DermaClose and DermaClose XL Continuous External Tissue Expander (CETE) devices to reduce wound size and/or assist with closure in acute full thickness wounds of the skin and assess the need for skin grafting for patients undergoing a four-compartment leg fasciotomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Wound of Skin

Currently open trials in the same condition.

Other Baxter Healthcare Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05330767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing